Loading quotes...

Forecast

The analysts' average price target is €3.95 (+154.84%). The median is €3.59 (+131.61%).

Buy	5
Hold	4
Sell	0

News Go to news feed

Tenax Therapeutics: phase‑3 data on TNX‑103 show primary endpoint missed, subgroup with benefit

Tenax Therapeutics presented results from the Phase‑3 LEVEL study of TNX‑103 for pulmonary hypertension in HFpEF at the ESC Congress. The primary endpoint (change in 6‑minute walk distance at 12 weeks) and a key secondary endpoint were not significant in the overall population. However, in patients with a baseline 6‑minute walk distance below the median, TNX‑103 showed an improvement of 26.3 m, a 47% reduction in NT‑proBNP and a lowering of systolic right ventricular pressure; the drug was overall well tolerated and Tenax plans more targeted patient selection for LEVEL‑2 and further global development. » More on de.investing.com

Financials

In the last quarter, Tenax Therapeutics Aktie had revenue of €0 and net profit of -€15.6m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-15.6m	69.50%
EBITDA	-16.46m	78.84%

Fundamentals

Metric	Value
Market capitalization	€40.93m
Number of shares	26.53m
52-week high/low	€17.40 - €1.18
Dividends	No
Beta	0.92
P/E ratio	-1.15
PEG ratio	0.03
P/B ratio	0.77
P/S ratio	0.00

Company profile

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.